weight loss semaglutide thibodaux tirzepatide vs safety profile versus Once Weekly in Patients with Type 2 Diabetes Semaglutide vs. Tirzepatide for Obesity – Weight Loss Dynamics and Health

Most patients report noticing reduced appetite within the first 1-2 weeks at the starting dose (0.25mg for Wegovy)

Call 911 or go to the emergency room if you experience severe abdominal pain (especially if radiating to your back), persistent vomiting, signs of dehydration, confusion, difficulty breathing, or if you cannot reach your healthcare provider when experiencing concerning symptoms

Marta S, Maria RA, Amparo A-P

UBT251 is classified as a Class 1 innovative drug in China and has recently been approved for clinical trials in adults with type 2 diabetes, fatty liver disease, and chronic kidney disease

van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA